What is HC Wainwright’s Forecast for GPCR FY2027 Earnings?

Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR) – Stock analysts at HC Wainwright lifted their FY2027 earnings per share (EPS) estimates for Structure Therapeutics in a report issued on Monday, March 16th. HC Wainwright analyst A. Ghosh now forecasts that the company will post earnings of ($2.27) per share for the year, up from their prior estimate of ($2.34). HC Wainwright currently has a “Buy” rating and a $100.00 target price on the stock. The consensus estimate for Structure Therapeutics’ current full-year earnings is ($0.82) per share. HC Wainwright also issued estimates for Structure Therapeutics’ FY2028 earnings at ($2.37) EPS, FY2029 earnings at ($2.46) EPS and FY2030 earnings at ($2.25) EPS.

Several other research firms also recently weighed in on GPCR. William Blair reaffirmed an “outperform” rating on shares of Structure Therapeutics in a report on Monday. The Goldman Sachs Group raised shares of Structure Therapeutics to a “strong-buy” rating in a research note on Tuesday, January 20th. BMO Capital Markets set a $145.00 price target on shares of Structure Therapeutics and gave the stock an “outperform” rating in a research report on Tuesday. JPMorgan Chase & Co. increased their price objective on shares of Structure Therapeutics from $65.00 to $105.00 and gave the company an “overweight” rating in a report on Thursday, January 22nd. Finally, Stifel Nicolaus boosted their target price on Structure Therapeutics from $50.00 to $90.00 and gave the stock a “buy” rating in a report on Monday, December 8th. Two investment analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and two have given a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $110.00.

Structure Therapeutics Stock Performance

NASDAQ:GPCR opened at $56.15 on Wednesday. The stock has a market cap of $3.98 billion, a price-to-earnings ratio of -71.08 and a beta of -1.80. Structure Therapeutics has a 1 year low of $13.22 and a 1 year high of $94.90. The business has a fifty day moving average of $73.19 and a 200-day moving average of $50.24.

Structure Therapeutics (NASDAQ:GPCR) last posted its earnings results on Thursday, February 26th. The company reported ($0.49) EPS for the quarter, missing the consensus estimate of ($0.35) by ($0.14).

Hedge Funds Weigh In On Structure Therapeutics

Several hedge funds have recently made changes to their positions in the business. CWM LLC lifted its stake in Structure Therapeutics by 35.2% during the fourth quarter. CWM LLC now owns 480 shares of the company’s stock valued at $33,000 after purchasing an additional 125 shares during the last quarter. EverSource Wealth Advisors LLC increased its holdings in shares of Structure Therapeutics by 530.0% in the third quarter. EverSource Wealth Advisors LLC now owns 1,071 shares of the company’s stock valued at $30,000 after buying an additional 901 shares in the last quarter. State of Wyoming acquired a new stake in shares of Structure Therapeutics during the 2nd quarter valued at $28,000. Police & Firemen s Retirement System of New Jersey bought a new stake in shares of Structure Therapeutics during the 4th quarter worth $127,000. Finally, Banque Cantonale Vaudoise acquired a new position in shares of Structure Therapeutics in the 4th quarter worth $205,000. Institutional investors and hedge funds own 91.78% of the company’s stock.

Key Structure Therapeutics News

Here are the key news stories impacting Structure Therapeutics this week:

• Positive Sentiment: ACCESS II topline: Strong phase‑2 results — large, sustained weight loss (16%+ placebo‑adjusted) at 44 weeks for aleniglipron, positioning it as a leading oral GLP‑1 candidate. Structure Therapeutics Reports Positive Topline Data from Phase 2 ACCESS II Trial with Once-Daily Oral Small Molecule GLP-1 Receptor Agonist, Aleniglipron
• Positive Sentiment: Broad investor/media pickup and analyst coverage amplified the move — detailed slides/transcript and multiple outlets highlighted the data and its implications for the oral GLP‑1 market. Structure Therapeutics Inc. (GPCR) Discusses Positive Topline Results from ACCESS II and Related Studies of Aleniglipron Oral GLP-1 – Slideshow
• Positive Sentiment: Market reaction: Several outlets reported sharp intraday gains (including a ~10% jump in some sessions) as investors priced in competitive positioning in the weight‑loss pill race. Structure Therapeutics (GPCR) Stock Jumps 10% After Breakthrough GLP-1 Weight Loss Data
• Neutral Sentiment: Analyst update: HC Wainwright lowered its price target from $114 to $100 but maintained a “buy” rating — still a sizable implied upside, but the cut may temper immediate upside expectations. Benzinga
• Neutral Sentiment: Sector positioning: Commentary and lists now highlight GPCR among leading oral GLP‑1 competitors — helpful for visibility but increases competitive scrutiny and valuation comparisons. 3 Companies at the Forefront of the GLP-1 Pill Wars (GPCR)
• Negative Sentiment: Near‑term volatility: After the big run‑up, profit‑taking and normal rotation have pushed shares lower today; expect continued choppy trading as the market digests how oral efficacy converts into regulatory, safety and commercial outcomes. Inside Biotech: Structure Therapeutics jolts oral GLP-1 race with mid-stage data

Structure Therapeutics Company Profile

Structure Therapeutics (NASDAQ:GPCR) is a clinical‐stage biotechnology company focused on the discovery and development of oral small‐molecule therapies that target G protein‐coupled receptors (GPCRs). Leveraging advances in structural biology, computational chemistry and medicinal chemistry, the company’s scientific platform is designed to optimize binding interactions and pharmacokinetic properties, with the goal of delivering innovative treatments for metabolic and inflammatory disorders.

The company’s pipeline comprises multiple programs in various stages of preclinical and clinical development.